Top Stars Performers Credit Coordinated Messaging, Targeted Outreach

As CMS resumed normal Star Ratings calculations and gave greater weight to patient experience measures, the proportion of Medicare Advantage Prescription Drug (MA-PD) plans earning 4 stars or higher for 2023 saw a dramatic drop from 2022, according to newly released CMS data. In an AIS Health series on successful Star Ratings strategies, top performers highlight connecting the dots around medication adherence, maintaining a year-round focus on member experience, and helping members navigate and utilize their benefits as key priorities. And while member outreach is a critical part of those initiatives, successful plans are careful to avoid overcommunicating with members and creating message fatigue, sources tell AIS Health, a division of MMIT.

© 2022 MMIT
Lauren Flynn Kelly

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues, including drug benefits and specialty pharmacy, for more than a decade. She served as editor of Drug Benefit News (the predecessor to Radar on Drug Benefits) from 2004 to 2005 and again from 2011 to 2016, and now manages Radar on Medicare Advantage. Lauren graduated from Vassar College with a B.A. in English.

Related Posts

rx-bottle
July 21

Plans Build Trust, Mine Data to Dash Medication Adherence Barriers

READ MORE
pill-bottle-hands
September 1

BCBSRI Achieved Savings, 5-Star Rating With Help of Embedded ACO Pharmacists

READ MORE
elderly-people-calculating
February 3

Potential 5-Star SEP Disruption Depends on Marketing Prowess

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today